Pioglitazone in nonalcoholic steatohepatitis.
Ota
Tsuguhito
T
Takamura
Toshinari
T
Kaneko
Shuichi
S
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000473:pathology; D009765:Obesity / Q000503:physiopathology; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone